Zhong C - Search Results

1

Therapeutic Application of Natural Medicine Monomers in Cancer Treatment.

Zhong C, Wall NR, Zu Y, Sui G. Zhong C, et al. Curr Med Chem. 2017 Nov 17;24(34):3681-3697. doi: 10.2174/0929867324666170714101503. Curr Med Chem. 2017. PMID: 28714385 Review.

2

Ellagic acid synergistically potentiates inhibitory activities of chemotherapeutic agents to human hepatocellular carcinoma.

Zhong C, Qiu S, Li J, Shen J, Zu Y, Shi J, Sui G. Zhong C, et al. Phytomedicine. 2019 Jun;59:152921. doi: 10.1016/j.phymed.2019.152921. Epub 2019 Apr 4. Phytomedicine. 2019. PMID: 31055231

3

Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells.

Qiu S, Zhong C, Zhao B, Li G, Wang J, Jehan S, Li J, Zhao X, Li D, Sui G. Qiu S, et al. Among authors: zhong c. Biochim Biophys Acta Gen Subj. 2021 Jul;1865(7):129911. doi: 10.1016/j.bbagen.2021.129911. Epub 2021 Apr 20. Biochim Biophys Acta Gen Subj. 2021. PMID: 33862123

4

The high water solubility of inclusion complex of taxifolin-γ-CD prepared and characterized by the emulsion solvent evaporation and the freeze drying combination method.

Zu Y, Wu W, Zhao X, Li Y, Zhong C, Zhang Y. Zu Y, et al. Among authors: zhong c. Int J Pharm. 2014 Dec 30;477(1-2):148-58. doi: 10.1016/j.ijpharm.2014.10.027. Epub 2014 Oct 16. Int J Pharm. 2014. PMID: 25455767

5

Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status.

Jehan S, Zhong C, Li G, Zulqarnain Bakhtiar S, Li D, Sui G. Jehan S, et al. Among authors: zhong c. Front Pharmacol. 2020 Sep 15;11:555283. doi: 10.3389/fphar.2020.555283. eCollection 2020. Front Pharmacol. 2020. PMID: 33041795 Free PMC article.

6

Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.

Zu Y, Wu W, Zhao X, Li Y, Wang W, Zhong C, Zhang Y, Zhao X. Zu Y, et al. Among authors: zhong c. Int J Pharm. 2014 Aug 25;471(1-2):366-76. doi: 10.1016/j.ijpharm.2014.05.049. Epub 2014 Jun 2. Int J Pharm. 2014. PMID: 24882039

7

Preparation and characterization of micronized ellagic acid using antisolvent precipitation for oral delivery.

Li Y, Zhao X, Zu Y, Zhang Y, Ge Y, Zhong C, Wu W. Li Y, et al. Among authors: zhong c. Int J Pharm. 2015;486(1-2):207-16. doi: 10.1016/j.ijpharm.2015.03.071. Epub 2015 Apr 1. Int J Pharm. 2015. PMID: 25841566

8

Disruption of YY1-EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development.

Yi C, Li G, Wang W, Sun Y, Zhang Y, Zhong C, Stovall DB, Li D, Shi J, Sui G. Yi C, et al. Among authors: zhong c. Cancers (Basel). 2021 May 16;13(10):2402. doi: 10.3390/cancers13102402. Cancers (Basel). 2021. PMID: 34065631 Free PMC article.

9

A histidine cluster determines YY1-compartmentalized coactivators and chromatin elements in phase-separated enhancer clusters.

Wang W, Qiao S, Li G, Cheng J, Yang C, Zhong C, Stovall DB, Shi J, Teng C, Li D, Sui G. Wang W, et al. Among authors: zhong c. Nucleic Acids Res. 2022 May 20;50(9):4917-4937. doi: 10.1093/nar/gkac233. Nucleic Acids Res. 2022. PMID: 35390165 Free PMC article.

10

Resveratrol-loaded glycyrrhizic acid-conjugated human serum albumin nanoparticles wrapping resveratrol nanoparticles: Preparation, characterization, and targeting effect on liver tumors.

Wu M, Lian B, Deng Y, Feng Z, Zhong C, Wu W, Huang Y, Wang L, Zu C, Zhao X. Wu M, et al. Among authors: zhong c. J Biomater Appl. 2017 Aug;32(2):191-205. doi: 10.1177/0885328217713357. Epub 2017 Jun 13. J Biomater Appl. 2017. PMID: 28610486

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,375 results

Search Page

Filters